Recently Featured

EMA Recommends Marketing Authorisation for Teizeild to Delay Type 1 Diabetes Onset

November 29, 2025
The European Medicines Agency (EMA) has recommended granting marketing authorisation for Teizeild (teplizumab), a first-in-class treatment aimed at delaying the onset of stage 3 type 1 diabetes in adults. This significant development marks a pivotal moment in diabetes management, as it offers a novel therapeutic approach to a condition that has long lacked preventive options.…

Biopharma Industry Gathers Momentum in Q3

November 29, 2025
The biopharma industry demonstrated significant growth in the third quarter of 2023, with key performance indicators reflecting an upward trend across various sectors. This momentum is attributed to increased investment in research and development, alongside a surge in demand for innovative therapies, particularly in oncology and rare diseases. As companies continue to navigate complex regulatory…

ByHeart Issues Nationwide Recall Amid Infant Botulism Outbreak Linked to Its Formula

November 29, 2025
ByHeart has initiated a nationwide recall of all its infant formula products following a concerning outbreak of infant botulism linked to its products. This unprecedented action comes as regulators have identified a connection between the formula and cases of botulism, a rare but potentially fatal illness typically associated with bacterial spores found in soil and…

The Era of Safe Bets in Psychiatric Medicine is Over

November 28, 2025
For decades, the pharmaceutical industry’s approach to mental health was a playbook of conservative, incremental innovation. The market was saturated with me-too drugs — slight variations on existing antidepressants and antipsychotics that offered predictable, modest returns. For investors, it was a safe bet. For patients suffering from the most severe forms of mental illness, it…

Ongoing Cases